 |
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
SPECIAL FEATURE |
*Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands; Columbia University, College of Physicians and Surgeons, New York, New York; Rush Medical College, Chicago, Illinois; Weill Medical College, Cornell University, New York, New York; ||University of Washington, Seattle, Washington; ¶Columbia Presbyterian Medical Center, New York, New York; #National Institutes of Health, Bethesda, Maryland; **Leiden University Medical Center, Leiden, The Netherlands; Imperial College Medical School, London, United Kingdom; San Carlo Borromeo Hospital, Milan, Italy; Vanderbilt University, Nashville, Tennessee; ||||SUNY Health Science Center, Brooklyn, New York; ¶¶Ohio State University, Columbus, Ohio; ##Georges Pompidou European Hospital, Paris, France; ***St. Vincent’s Hospital, Fitzroy, Victoria, Australia; University of North Carolina School of Medicine, Chapel Hill, North Carolina; University Kebangsaan Malaysia, Kuala Lumpur, Malaysia; Necker Hospital, Paris, France; ||||||University of Malaya Medical School, Kuala Lumpur, Malaysia; ¶¶¶Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan; ###Federal University of Sao Paulo, Sao Paulo, Brazil; and ****University of Tsubuka, Ibaraki, Japan
Correspondence to Dr. Jan J. Weening, Department of Pathology, Academic Medical Center University of Amsterdam, PO Box 22660, 1006 AZ Amsterdam, The Netherlands. Phone: 3120566410; Fax: 31206960389; E-mail: j.j.weening{at}amc.uva.nl
ABSTRACT. The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving <50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving 
50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions]. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.
This article has been cited by other articles:
 |
|
 |
|
  D. J. Hobbs, G.-M. Barletta, J. S. Rajpal, M. N. Rajpal, D. P. Weismantel, J. D. Birmingham, and T. E. Bunchman Severe paediatric systemic lupus erythematosus nephritis--a single-centre experience Nephrol. Dial. Transplant., February 1, 2010; 25(2): 457 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Richez, K. Yasuda, R. G. Bonegio, A. A. Watkins, T. Aprahamian, P. Busto, R. J. Richards, C. L. Liu, R. Cheung, P. J. Utz, et al. IFN Regulatory Factor 5 Is Required for Disease Development in the Fc{gamma}RIIB-/-Yaa and Fc{gamma}RIIB-/- Mouse Models of Systemic Lupus Erythematosus J. Immunol., January 15, 2010; 184(2): 796 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Y. Behara, W. L. Whittier, S. M. Korbet, M. M. Schwartz, M. Martens, and E. J. Lewis Pathogenetic features of severe segmental lupus nephritis Nephrol. Dial. Transplant., January 1, 2010; 25(1): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Moroni, C. Novembrino, S. Quaglini, R. De Giuseppe, B. Gallelli, V. Uva, V. Montanari, P. Messa, and F. Bamonti Oxidative stress and homocysteine metabolism in patients with lupus nephritis Lupus, January 1, 2010; 19(1): 65 - 72. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Isenberg, G. B. Appel, G. Contreras, M. A. Dooley, E. M. Ginzler, D. Jayne, J. Sanchez-Guerrero, D. Wofsy, X. Yu, and N. Solomons Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study Rheumatology, January 1, 2010; 49(1): 128 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Schiffer, P. Kumpers, Ana. M. Davalos-Misslitz, M. Haubitz, H. Haller, H.-J. Anders, T. Witte, and M. Schiffer B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE) Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3708 - 3712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Trivedi, M. Zeier, and J. Reiser Role of podocytes in lupus nephritis Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3607 - 3612. [Full Text] [PDF]
|
|
|
|
|
|
P. Esposito, M. M Balletta, A. Procino, L. Postiglione, and B. Memoli Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis Lupus, December 1, 2009; 18(14): 1329 - 1330. [PDF]
|
|
|
|
 |
|
 K. L. Gibson, D. S. Gipson, S. A. Massengill, M. A. Dooley, W. A. Primack, M. A. Ferris, and S. L. Hogan Predictors of Relapse and End Stage Kidney Disease in Proliferative Lupus Nephritis: Focus on Children, Adolescents, and Young Adults Clin. J. Am. Soc. Nephrol., December 1, 2009; 4(12): 1962 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. HIRAKI, S. M. BENSELER, P. N. TYRRELL, E. HARVEY, D. HEBERT, and E. D. SILVERMAN Ethnic Differences in Pediatric Systemic Lupus Erythematosus J Rheumatol, November 1, 2009; 36(11): 2539 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, X. Ding, and B. Chen Value of the RIFLE classification for acute kidney injury in diffuse proliferative lupus nephritis Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3115 - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Kumpers, S David, M Haubitz, J Hellpap, R Horn, V Brocker, M Schiffer, H Haller, and T Witte The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus Ann Rheum Dis, October 1, 2009; 68(10): 1638 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vachvanichsanong, P. Dissaneewate, and E. McNeil Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood-onset lupus nephritis: a 23-year experience in a single centre Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2729 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pan, C. Wu, H. Chen, C. Dang, F. Chang, H. Liu, C. Chu, M Lin, and Y. Lee Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan Lupus, July 1, 2009; 18(8): 698 - 704. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Seredkina, S. N. Zykova, and O. P. Rekvig Progression of Murine Lupus Nephritis Is Linked to Acquired Renal Dnase1 Deficiency and Not to Up-Regulated Apoptosis Am. J. Pathol., July 1, 2009; 175(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Jog, J.-A. Dinnall, S. Gallucci, M. P. Madaio, and R. Caricchio Poly(ADP-Ribose) Polymerase-1 Regulates the Progression of Autoimmune Nephritis in Males by Inducing Necrotic Cell Death and Modulating Inflammation J. Immunol., June 1, 2009; 182(11): 7297 - 7306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dhaun, P. Lilitkarntakul, I. M. MacIntyre, E. Muilwijk, N. R. Johnston, D. C. Kluth, D. J. Webb, and J. Goddard Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1477 - F1483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Appel, G. Contreras, M. A. Dooley, E. M. Ginzler, D. Isenberg, D. Jayne, L.-S. Li, E. Mysler, J. Sanchez-Guerrero, N. Solomons, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1103 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wagner, I Craici, D Reed, S Norby, K Bailey, H. Wiste, C. Wood, K. Moder, K. Liang, K. Liang, et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis Lupus, April 1, 2009; 18(4): 342 - 347. [Abstract] [PDF]
|
|
|
|
|
|
A. Wang, A.-M. Fairhurst, K. Tus, S. Subramanian, Y. Liu, F. Lin, P. Igarashi, X. J. Zhou, F. Batteux, D. Wong, et al. CXCR4/CXCL12 Hyperexpression Plays a Pivotal Role in the Pathogenesis of Lupus J. Immunol., April 1, 2009; 182(7): 4448 - 4458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Austin III, G. G. Illei, M. J. Braun, and J. E. Balow Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy J. Am. Soc. Nephrol., April 1, 2009; 20(4): 901 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Monteferrante, M Giani, and M. van den Heuvel Systemic lupus erythematosus and Wiskott-Aldrich syndrome in an Italian patient Lupus, March 1, 2009; 18(3): 273 - 277. [Abstract] [PDF]
|
|
|
|
|
|
L Zhu, X Yang, Y Ji, W Chen, W Guan, S. Zhou, and X Yu Up-regulated renal expression of TNF-{alpha} signalling adapter proteins in lupus glomerulonephritis Lupus, February 1, 2009; 18(2): 116 - 127. [Abstract] [PDF]
|
|
|
|
|
|
G Moroni, A Radice, G Giammarresi, S Quaglini, B Gallelli, A Leoni, M L Vecchi, P Messa, and R A Sinico Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis Ann Rheum Dis, February 1, 2009; 68(2): 234 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Benseler, J. M. Bargman, B. M. Feldman, P. N. Tyrrell, E. Harvey, D. Hebert, and E. D. Silverman Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome Rheumatology, February 1, 2009; 48(2): 176 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aprahamian, R. G. Bonegio, C. Richez, K. Yasuda, L.-K. Chiang, K. Sato, K. Walsh, and I. R. Rifkin The Peroxisome Proliferator-Activated Receptor {gamma} Agonist Rosiglitazone Ameliorates Murine Lupus by Induction of Adiponectin J. Immunol., January 1, 2009; 182(1): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Smyth and V. D. Garovic 25-Year-Old Man With Flank Pain, Hematuria, and Proteinuria Mayo Clin. Proc., January 1, 2009; 84(1): 72 - 75. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Marks, S. J. Williams, K. Tullus, and N. J. Sebire Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in paediatric lupus nephritis Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3521 - 3526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bao, Z.-H. Liu, H.-L. Xie, W.-X. Hu, H.-T. Zhang, and L.-S. Li Successful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy J. Am. Soc. Nephrol., October 1, 2008; 19(10): 2001 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Zulian, F. Pluchinotta, G Martini, L Da Dalt, and G Zacchello Severe clinical course of systemic lupus erythematosus in the first year of life Lupus, September 1, 2008; 17(9): 780 - 786. [Abstract] [PDF]
|
|
|
|
|
|
P. F. K. Yong, L. Aslam, M. Y. Karim, and M. A. Khamashta Management of hypogammaglobulinaemia occurring in patients with systemic lupus erythematosus Rheumatology, September 1, 2008; 47(9): 1400 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Piccolo, P. Lisi, E. Valicenti, G. Pannarale, and P. Coratelli Clinical and histological features of lupus nephritis induced by anti-TNF{alpha} therapy NDT Plus, August 1, 2008; 1(4): 221 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yu, Y. Chen, J. Lan, C. Cheng, C. Chen, M. Wu, and K. Shu Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation Lupus, July 1, 2008; 17(7): 687 - 694. [Abstract] [PDF]
|
|
|
|
|
|
H Ciferska, P Horak, Y. Konttinen, K Krejci, T Tichy, Z Hermanova, and J Zadrazil Expression of nucleic acid binding Toll-like receptors in control, lupus and transplanted kidneys - a preliminary pilot study Lupus, June 1, 2008; 17(6): 580 - 585. [Abstract] [PDF]
|
|
|
|
|
|
K. Friebe, R. Waldherr, and M. Krautter Viral haemorrhagic fever and a skin rash--what is the link? NDT Plus, June 1, 2008; 1(3): 178 - 181. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zheng, R. Sinniah, and S. I-H. Hsu Pathogenic Role of NF-{kappa}B Activation in Tubulointerstitial Inflammatory Lesions in Human Lupus Nephritis J. Histochem. Cytochem., May 1, 2008; 56(5): 517 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hiramatsu, T. Kuroiwa, H. Ikeuchi, A. Maeshima, Y. Kaneko, K. Hiromura, K. Ueki, and Y. Nojima Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions Rheumatology, May 1, 2008; 47(5): 702 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Schwartz, S. M. Korbet, E. J. Lewis, and for the Collaborative Study Group The prognosis and pathogenesis of severe lupus glomerulonephritis Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1298 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hidaka, Y. Suzuki, M. Yamashita, T. Shibata, Y. Tanaka, S. Horikoshi, and Y. Tomino Amelioration of Crescentic Glomerulonephritis by RhoA Kinase Inhibitor, Fasudil, through Podocyte Protection and Prevention of Leukocyte Migration Am. J. Pathol., March 1, 2008; 172(3): 603 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Mortensen, K. A. Fenton, and O. P. Rekvig Lupus Nephritis: The Central Role of Nucleosomes Revealed Am. J. Pathol., February 1, 2008; 172(2): 275 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kasitanon, M. Petri, M. Haas, L.S. Magder, and D.M. Fine Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases Lupus, January 1, 2008; 17(1): 40 - 45. [Abstract] [PDF]
|
|
|
|
|
|
C. Grootscholten, I. M. Bajema, S. Florquin, E. J. Steenbergen, C. J. Peutz-Kootstra, R. Goldschmeding, M. Bijl, E. C. Hagen, H. C. van Houwelingen, R. H. W. M. Derksen, et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis Nephrol. Dial. Transplant., January 1, 2008; 23(1): 223 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E. Chen, S. M. Korbet, R. S. Katz, M. M. Schwartz, E. J. Lewis, and for the Collaborative Study Group Value of a Complete or Partial Remission in Severe Lupus Nephritis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus, December 1, 2007; 16(12): 972 - 980. [Abstract] [PDF]
|
|
|
|
|
|
I. C L Kremer Hovinga, M. Koopmans, H. J Baelde, E. de Heer, J. A Bruijn, and I. M Bajema Tissue chimerism in systemic lupus erythematosus is related to injury Ann Rheum Dis, December 1, 2007; 66(12): 1568 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S-J. Li, Z-H. Liu, C-H. Zen, Q-W. Wang, Y. Wang, and L-S. Li Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection Lupus, November 1, 2007; 16(11): 875 - 880. [Abstract] [PDF]
|
|
|
|
|
|
N. Kasitanon, D.M. Fine, M. Haas, L.S. Magder, and M. Petri Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations Lupus, November 1, 2007; 16(11): 887 - 895. [Abstract] [PDF]
|
|
|
|
|
|
J. Wang, W. Hu, H. Xie, H. Zhang, H. Chen, C. Zeng, Z. Liu, and L. Li Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide Lupus, September 1, 2007; 16(9): 707 - 712. [Abstract] [PDF]
|
|
|
|
|
|
G. Moroni, S. Quaglini, B. Gallelli, G. Banfi, P. Messa, and C. Ponticelli The long-term outcome of 93 patients with proliferative lupus nephritis Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2531 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.R. Pluchinotta, B. Schiavo, F. Vittadello, G. Martini, G. Perilongo, and F. Zulian Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes Lupus, August 1, 2007; 16(8): 550 - 555. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Isenberg, J. J. Manson, M. R. Ehrenstein, and A. Rahman Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology, July 1, 2007; 46(7): 1052 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.M. Stinton, S.G. Barr, L.A. Tibbles, S. Yilmaz, A. Sar, H. Benedikttson, and M.J. Fritzler Autoantibodies in lupus nephritis patients requiring renal transplantation Lupus, June 1, 2007; 16(6): 394 - 400. [Abstract] [PDF]
|
|
|
|
|
|
T. Yamamoto, T. Nakagawa, H. Suzuki, N. Ohashi, H. Fukasawa, Y. Fujigaki, A. Kato, Y. Nakamura, F. Suzuki, and A. Hishida Urinary Angiotensinogen as a Marker of Intrarenal Angiotensin II Activity Associated with Deterioration of Renal Function in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1558 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Korbet, M. M. Schwartz, J. Evans, E. J. Lewis, and for the Collaborative Study Group Severe Lupus Nephritis: Racial Differences in Presentation and Outcome J. Am. Soc. Nephrol., January 1, 2007; 18(1): 244 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brukamp, A. M. Doyle, R. D. Bloom, N. Bunin, J. E. Tomaszewski, and B. Cizman Nephrotic Syndrome after Hematopoietic Cell Transplantation: Do Glomerular Lesions Represent Renal Graft-versus-Host Disease? Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 685 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Kasitanon, D M Fine, M Haas, L S Magder, and M Petri Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis Lupus, June 1, 2006; 15(6): 366 - 370. [Abstract] [PDF]
|
|
|
|
|
|
T S Han, M M Schwartz, and E J Lewis Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis Lupus, February 1, 2006; 15(2): 71 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 W. W. Williams Jr., J. L. Ecker, R. I. Thadhani, and A. Rahemtullah Case 38-2005 -- A 29-Year-Old Pregnant Woman with the Nephrotic Syndrome and Hypertension N. Engl. J. Med., December 15, 2005; 353(24): 2590 - 2600. [Full Text] [PDF]
|
|
|
|
|
|
A. R. Kitching More Targeted Treatments for Lupus Nephritis: Is the Future (Nearly) Here? J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3146 - 3148. [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Karim, C. N. Pisoni, L. Ferro, M. F. Tungekar, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy Rheumatology, October 1, 2005; 44(10): 1317 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Stokes, K. Foster, G. S. Markowitz, F. Ebrahimi, W. Hines, D. Kaufman, B. Moore, D. Wolde, and V. D. D'Agati Development of glomerulonephritis during anti-TNF-{alpha} therapy for rheumatoid arthritis Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1400 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Daikha-Dahmane, J P Bault, D Molina-Gomes, D Hillion, and Y Ville Lupus erythematosus proliferative glomerulonephritis in fetus Lupus, April 1, 2005; 14(4): 326 - 327. [Abstract] [PDF]
|
|
|
|
|
|
T.-M. Chan, K.-C. Tse, C. S.-O. Tang, M.-Y. Mok, F.-K. Li, and for the Hong Kong Nephrology Study Group Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1076 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Turkmen, A Soylu, K Demir, B Kasap, S Sarioglu, and S Kavukcu Letter to the Editor Lupus, February 1, 2005; 14(2): 171 - 173. [PDF]
|
|
|
|
|
|
E J Lewis and M M Schwartz Pathology of lupus nephritis Lupus, January 1, 2005; 14(1): 31 - 38. [Abstract] [PDF]
|
|
|
|
|
|
F. A. Houssiau Management of Lupus Nephritis: An Update J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2694 - 2704. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Somers, G. H. Daouk, and R. T. McCluskey Case 11-2004 - A Boy with Rash, Edema, and Hypertension N. Engl. J. Med., April 8, 2004; 350(15): 1550 - 1559. [Full Text] [PDF]
|
|
|
|
|
|
Robin Goodfellow (43-4) Rheumatology, April 1, 2004; 43(4): 540 - 540. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Glassock Reclassification of Lupus Glomerulonephritis: Back to the Future J. Am. Soc. Nephrol., February 1, 2004; 15(2): 501 - 503. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
